Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
作者信息
Soderquist R, Bates D J P, Danilov A V, Eastman A
机构信息
1] Department of Pharmacology and Toxicology, Giesel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH, USA [2] Norris Cotton Cancer Center, Giesel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH, USA.
出版信息
Leukemia. 2013 Nov;27(11):2262-4. doi: 10.1038/leu.2013.138. Epub 2013 May 3.
Abstract
摘要
相似文献
1
Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
Leukemia. 2013 Nov;27(11):2262-4. doi: 10.1038/leu.2013.138. Epub 2013 May 3.
2
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Blood. 2015 Jul 16;126(3):363-72. doi: 10.1182/blood-2014-10-604975. Epub 2015 Jun 4.
3
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.
4
Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Cancer Res. 2012 Jun 15;72(12):3069-79. doi: 10.1158/0008-5472.CAN-11-4106. Epub 2012 Apr 23.
5
Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Leukemia. 2012 Jun;26(6):1433-5. doi: 10.1038/leu.2011.370. Epub 2012 Jan 6.
6
Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.
Mol Cancer Ther. 2013 Aug;12(8):1504-14. doi: 10.1158/1535-7163.MCT-12-1197. Epub 2013 May 30.
7
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Cancer. 2012 Feb 15;118(4):1023-31. doi: 10.1002/cncr.26360. Epub 2011 Jul 14.
8
The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
Apoptosis. 2014 Jan;19(1):201-9. doi: 10.1007/s10495-013-0910-y.
9
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Br J Pharmacol. 2016 Feb;173(3):471-83. doi: 10.1111/bph.13370. Epub 2016 Jan 16.
10
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.
引用本文的文献
1
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer.
Cell Death Dis. 2025 Mar 12;16(1):170. doi: 10.1038/s41419-025-07481-8.
2
In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPER.
Sci Rep. 2023 Oct 20;13(1):17933. doi: 10.1038/s41598-023-43860-x.
3
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.
Int J Mol Sci. 2021 Sep 28;22(19):10442. doi: 10.3390/ijms221910442.
4
AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA.
Cancers (Basel). 2020 Aug 15;12(8):2298. doi: 10.3390/cancers12082298.
5
Nuphar alkaloids induce very rapid apoptosis through a novel caspase-dependent but BAX/BAK-independent pathway.
Cell Biol Toxicol. 2019 Oct;35(5):435-443. doi: 10.1007/s10565-019-09469-5. Epub 2019 Mar 2.
6
SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Haematologica. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24.
7
The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Target Oncol. 2017 Oct;12(5):677-687. doi: 10.1007/s11523-017-0509-2.
8
Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance.
Drug Des Devel Ther. 2017 Jun 19;11:1803-1813. doi: 10.2147/DDDT.S133127. eCollection 2017.
9
Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Oncotarget. 2017 Mar 28;8(13):21128-21139. doi: 10.18632/oncotarget.15050.
10
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
Mol Cancer Ther. 2016 Sep;15(9):2011-7. doi: 10.1158/1535-7163.MCT-16-0031. Epub 2016 Aug 17.
本文引用的文献
1
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
2
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Blood. 2012 Jun 14;119(24):5807-16. doi: 10.1182/blood-2011-12-400929. Epub 2012 Apr 26.
3
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19.
4
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.
5
Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
J Biol Chem. 2011 Jul 15;286(28):24882-95. doi: 10.1074/jbc.M111.255828. Epub 2011 May 31.
6
Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.
Cell Death Differ. 2011 May;18(5):864-73. doi: 10.1038/cdd.2010.152. Epub 2010 Nov 26.
7
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Blood. 2011 Jan 6;117(1):156-64. doi: 10.1182/blood-2010-01-262808. Epub 2010 Oct 22.
8
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
Clin Cancer Res. 2009 May 1;15(9):3172-6. doi: 10.1158/1078-0432.CCR-08-2985. Epub 2009 Apr 14.
9
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.
10
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Mol Cancer Ther. 2008 Jul;7(7):2192-202. doi: 10.1158/1535-7163.MCT-08-0333.
Zotero 插件